Eberhard Standl
Endocrinology, Diabetes and Metabolism · 2004–2019
A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Endocrinology, Diabetes and Metabolism — 26 citations into it
Whom Eberhard Standl trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- G. Moneta (in Endocrinology, Diabetes and Metabolism)
Papers from Eberhard Standl's perspective
Ordered by how strongly the researchers Eberhard Standl trusts endorse each paper. Same corpus, a different order for every researcher.
- Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). (Kidney International)
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes (New England Journal of Medicine)
- Effect of a multifactorial intervention on mortality in type 2 diabetes. (New England Journal of Medicine)
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (Cardiovascular Diabetology)
- Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1·9 million people. (The Lancet)
- Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity (Circulation Research)
- Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes – Mechanisms, Management, and Clinical Considerations (Circulation)
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. (The Lancet)
- IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
Their papers
- Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications (2019) — 841 citations
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. (2015) — 2,285 citations
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. (2005) — 4,141 citations
- The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. (2004) — 679 citations